Transgender Estradiol Affirming Therapy

Status Recruiting

Clinical Trial Summary

The purpose of this open label, pilot, randomized clinical trial is to evaluate the effectiveness, safety and tolerability of estrogen use in transgender female and the degree of testosterone suppression achieved in this population when placed on gender affirming pharmacological therapy.

Clinical Trial Description

Transgender patients suffer from poor mental and medical health outcomes compared to their cisgender peers. Given the widespread acknowledgment of the health care needs of transgender people, priority should be given to those actions that will ensure safe and appropriate care in health centers. The current hormone therapy is not uniform and depends on the health care system, cost considerations, and differences in the regional availability of estrogens and antiandrogens. A typical regimen includes estrogen to provide feminizing effects in conjunction with therapy to block testosterone (antiandrogens or gonadotropin-releasing hormone [GnRH] analogs). Estrogen also inhibits testosterone secretion. Ethinyl estradiol was previously the mainstay of most estrogen-directed therapies; this is no longer the case due to its increased risk of cardiovascular death and increased incidence of deep venous thrombosis. 17-beta estradiol, which can be provided in tablet, patch, and injection, is currently the preferred formulation. This open label, pilot, randomized clinical trial will evaluate the effectiveness and safety of gender affirming hormone therapy with estrogen and the degree of testosterone suppression achieved in transgender female patients when placed on daily sublingual 17-beta estradiol, twice daily sublingual 17-beta estradiol, or transdermal 17-beta estradiol. All patients will also receive spironolactone as antiandrogen. One of the major complications from estradiol GAHT is thromboembolism. The investigators will also determine the effects of the different estradiol regimens on thrombosis markers. These studies will be the first to determine if the dosing regimen of estradiol affects risk markers in transgender women. ;

Study Design

Related Conditions & MeSH terms

Transgenderism

Clinical Trial Details

NCT number	NCT05010707
Study type	Interventional
Source	Washington University School of Medicine
Contact	Samuel Cortez, MD
Phone	314-286-2339
Email	scortez@wustl.edu
Status	Recruiting
Phase	Phase 2
Start date	August 2, 2021
Completion date	January 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06093724` - Prospective Imaging Assessment of Perineo-pelvic Static's Evolution After Sexual Reassignment Surgery in MtF Transgender Patient, by Peno-scrotal Inversion Vaginoplasty Technique (TRANSPELV)	N/A
Recruiting	`NCT04977765` - Cardiometabolic Health in Transgender Males
Recruiting	`NCT06074796` - The Determinants of Fertility Preservation in TRANSgender Patients.
Completed	`NCT04454970` - Safe Access for Bladder Entry in Transgender Men Following Penile Reconstruction	N/A
Completed	`NCT04708600` - Effectiveness of Speech Therapy in Trans Women.	N/A
Terminated	`NCT04551144` - Effect of Transgender Therapy on Muscle, Fat and Tissue Receptors
Completed	`NCT04545450` - Effects of Testosterone Plus Dutasteride or Placebo on Muscle Strength, Body Composition and Metabolism in Transmen	Phase 3
Recruiting	`NCT05663892` - Drug-Drug Interaction Study in Trans Women Living With HIV	Phase 4
Completed	`NCT05666102` - Transgender Men's Perspectives on HIV Risk and HIV Prevention Interventions	N/A
Recruiting	`NCT04838249` - Effects of Cross-sex Hormone Therapy on Eating Behavior, Metabolism, Energy Balance and Cardiovascular System
Not yet recruiting	`NCT06434805` - An Education Initiative to Reduce Stigma Towards Sex Workers and Sexual Minorities Among Nursing Students	N/A
Recruiting	`NCT05883553` - Epithesis Versus Prosthesis in Post-phalloplasty Transgender Patients.	N/A
Not yet recruiting	`NCT04154358` - Implementing HPV DNA Self-Collection to Increase Rates of Cervical Cancer Screening in Transgender Men	N/A
Recruiting	`NCT04254354` - Transgender Men, Non-binary Persons and Testosterone Treatment BODY IDENTITY CLINIC
Completed	`NCT04969003` - Reducing Transphobia Among Adolescents Through a Brief Video Intervention	N/A
Completed	`NCT06149065` - Factors Associated With the Acne Severity Among Transmen Population: a Cross-sectional Study
Not yet recruiting	`NCT06443164` - Efficacy of a Chronic Pain Treatment Prior to Gender-affirming Surgery	N/A
Not yet recruiting	`NCT06450405` - Androgen Effects on the Reproductive Neuroendocrine Axis
Terminated	`NCT04275310` - Microeconomic Intervention to Reduce HIV Transmission in Economically Disadvantaged Transgender Women	N/A
Not yet recruiting	`NCT05415930` - Evaluation of an Adaptative, Multidisciplinary, Reach-out Program, Facilitating Pre Exposition HIV Prophylaxis (PrEP) Prescription and Retention in Care, in a Group of Trans Womens (TW) at High Risk of HIV Infection.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Transgender Estradiol Affirming Therapy — TREAT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms